| Compounds | Topics | Title | Date |
|---|---|---|---|
| cannabis,Dronabinol | gastroparesis via survey (n=197) | Cannabinoid Use in Patients With Gastroparesis and Related Disorders | Mar 2019 |
| A third of patients with Gp symptoms actively use cannabinoids for their chronic symptoms. Most of these patients perceive improvement in their symptoms with cannabinoids. | |||
| Nabilone,Dronabinol | cud in humans via placebo trial (n=14) | Subjective, cognitive, and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers | Jan 2012 |
|
Ingestion Method: nabilone (2, 4, 6, 8 mg), dronabinol (10, 20 mg) Nabilone (4, 6, 8 mg) and dronabinol (10, 20 mg) increased ratings of feeling a good effect, a strong effect, and/or `high' relative to placebo; nabilone had a slower onset of peak subjective effects than dronabinol. Nabilone (6, 8 mg) modestly lowered psychomotor speed relative to placebo and dronabinol. | |||
| Dronabinol | appetite boost,sleep,cancer in humans via placebo trial (n=47/65) | Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. | Sep 2011 |
| Positive THC-treated patients reported improved (P = 0.026) and enhanced (P < 0.001) chemosensory perception and food 'tasted better' (P = 0.04). Premeal appetite (P = 0.05) and proportion of calories consumed as protein increased compared with placebo (P = 0.008). THC-treated patients reported increased quality of sleep (P = 0.025) and relaxation (P = 0.045). | |||
| Dronabinol | appetite boost,hiv in humans via trial (n=139) | Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. | Feb 1995 |
| Positive Dronabinol was found to be safe and effective for anorexia associated with weight loss in patients with AIDS. | |||
| cannabis,Dronabinol | tourettes in humans via case study (n=2) | Speechlessness in Gilles de la Tourette Syndrome: Cannabis-Based Medicines Improve Severe Vocal Blocking Tics in Two Patients. | Aug 2017 |
| We report the cases of two young German male patients with treatment-resistant Tourette syndrome (TS), who suffer from incapacitating stuttering-like speech disfluencies caused by vocal blocking tics and palilalia. Case 1: a 19-year old patient received medical cannabis at a dose of 1 x 0.1 g cannabis daily. Case 2: a 16-year old patient initially received dronabinol at a maximum dose of 22.4-33.6 mg daily. Both treatments provided significant symptom improvement of vocal blocking tics as well as of comorbid conditions and were well tolerated. Thus, cannabis-based medicine appears to be effective in treatment-resistant TS patients with vocal blocking tics. | |||